Venture capital firm applies pharmaceutical companies' approach to drug discovery to its business model to create an incubation partnership.

The common litany of complaints about independent venture capital (VC) firms is that many are increasingly trying to invest in older and larger companies in order to reduce the chances the investment will be lost and also for the handful of successful groups to put their larger funds to work more easily. But such trends have left individuals, so-called angels, and specialist, often-government-backed funds to try to seed ideas and support early-stage businesses.

However, alongside the handful of successful incubators,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?